Amarin Board of Directors Announces Appointment of Murray W. Stewart, DM FRCP
10 January 2023 - 11:00PM
Amarin Corporation plc (NASDAQ:AMRN) today announced that Murray W.
Stewart, D.M., F.R.C.P., has been appointed to the Company’s Board
of Directors. Following the appointment of Dr. Stewart, the Amarin
Board will be made up of approximately 70 percent of new
independent directors who were named to the Board over the last 12
months.
“As we focus on launching in Europe and
diversifying our product portfolio, adding Dr. Stewart to our Board
brings exceptional expertise in cardiometabolic research and
clinical development,” said Per Wold-Olsen, Chairman of the Board
of Directors, Amarin. “Dr. Stewart’s global and cardiovascular
disease experience and expertise will help support our efforts as
we advance both our European and International strategy as a
Company, and we are thrilled to have him join our Board of
Directors.”
Dr. Stewart is a physician by training and
brings more than 30 years of cardiometabolic academic and industry
experience to the Amarin Board of Directors. As a Consultant
Physician with the National Health Service (NHS) in the United
Kingdom (UK), Dr. Stewart led clinical teams in diabetes and
general medicine. During his 18-year tenure at GlaxoSmithKline
(GSK), Dr. Stewart held multiple roles, including Chief Medical
Officer, Clinical Head of the Biopharma Unit and Therapy Area Head
for Metabolic and Cardiovascular diseases. Recently, Dr. Stewart
was Chief Medical Officer at Rhythm Pharmaceuticals where he was
responsible for the development of new medicines and transforming
the care for patients with rare genetic diseases of Obesity. Dr.
Stewart holds a Bachelor of Medicine and a Doctor of Medicine from
Southampton Medical School in the UK and is a Fellow of the Royal
College of Physicians.
As part of the Company’s focus on stronger
corporate governance, Amarin has named six new members to the
Company’s board of directors over the last 12 months, including Dr.
Murray Stewart. The Board replenishment process has sought to
address the changing needs of the company as its strategy focuses
on becoming a global, diversified, cardiometabolic player,
including expertise in financial governance, international
commercialization, global clinical development and other areas to
support the Company’s strategy.
About AmarinAmarin is an innovative
pharmaceutical company leading a new paradigm in cardiovascular
disease management. From our foundation in scientific research to
our focus on clinical trials, and now our commercial expansion, we
are evolving and growing rapidly. Amarin has offices in
Bridgewater, New Jersey in the United States, Dublin in Ireland,
Zug in Switzerland, and other countries in Europe as well as
commercial partners and suppliers around the world. We are
committed to increasing the scientific understanding of the
cardiovascular risk that persists beyond traditional therapies and
advancing the treatment of that risk.
Forward-Looking StatementsThis press release
contains forward-looking statements which are made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995, including beliefs about Amarin’s replenishment process
for its Board of Directors; Amarin’s focus on becoming a global,
diversified, cardiometabolic player; and the overall potential and
future success of VASCEPA/VAZKEPA and Amarin generally. These
forward-looking statements are not promises or guarantees and
involve substantial risks and uncertainties. A further list and
description of these risks, uncertainties and other risks
associated with an investment in Amarin can be found in Amarin's
filings with the U.S. Securities and Exchange Commission, including
Amarin’s annual report on Form 10-K for the full year ended 2021.
Existing and prospective investors are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date they are made. Amarin undertakes no obligation to
update or revise the information contained in its forward-looking
statements, whether as a result of new information, future events
or circumstances or otherwise. Amarin’s forward-looking statements
do not reflect the potential impact of significant transactions the
company may enter into, such as mergers, acquisitions,
dispositions, joint ventures or any material agreements that Amarin
may enter into, amend or terminate.
Availability of Other Information About
AmarinAmarin communicates with its investors and the
public using the company website (www.amarincorp.com) and the
investor relations website (investor.amarincorp.com), including but
not limited to investor presentations and FAQs, Securities and
Exchange Commission filings, press releases, public conference
calls and webcasts. The information that Amarin posts on these
channels and websites could be deemed to be material information.
As a result, Amarin encourages investors, the media and others
interested in Amarin to review the information that is posted on
these channels, including the investor relations website, on a
regular basis. This list of channels may be updated from time to
time on Amarin’s investor relations website and may include social
media channels. The contents of Amarin’s website or these channels,
or any other website that may be accessed from its website or these
channels, shall not be deemed incorporated by reference in any
filing under the Securities Act of 1933.
Amarin Contact InformationInvestor
Inquiries:Lisa DeFrancescoAmarin Corporation
plcIR@amarincorp.comMedia Inquiries:Mark MarmurAmarin Corporation
plcPR@amarincorp.com
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Apr 2023 to Apr 2024